{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T16:03:34Z","timestamp":1790352214666,"version":"4.1.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"DOI":"10.1007\/s11255-026-05307-w","type":"journal-article","created":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T19:24:18Z","timestamp":1784921058000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy of telitacicept on renal outcomes in patients with biopsy-proven lupus nephritis: a 12-month follow-up pilot study"],"prefix":"10.1007","author":[{"given":"Tingmin","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zihan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jielong","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beibei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Lan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,24]]},"reference":[{"issue":"17","key":"5307_CR1","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1001\/jama.2024.2315","volume":"331","author":"CH Siegel","year":"2024","unstructured":"Siegel CH, Sammaritano LR (2024) Systemic lupus erythematosus: a review. JAMA 331(17):1480\u20131491","journal-title":"JAMA"},{"issue":"1s","key":"5307_CR2","first-page":"1S","volume":"105","author":"KDIGO","year":"2024","unstructured":"KDIGO (2024) Clinical practice guideline for the management of LUPUS NEPHRITIS. Kidney Int 105(1s):1S-s69","journal-title":"Kidney Int"},{"issue":"1","key":"5307_CR3","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2020-000389","volume":"7","author":"I Parodis","year":"2020","unstructured":"Parodis I, Tamirou F, Houssiau FA (2020) Prediction of prognosis and renal outcome in lupus nephritis. Lupus Sci Med 7(1):e000389","journal-title":"Lupus Sci Med"},{"key":"5307_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2022.102873","volume":"132","author":"L Arbitman","year":"2022","unstructured":"Arbitman L, Furie R, Vashistha H (2022) B cell-targeted therapies in systemic lupus erythematosus. J Autoimmun 132:102873","journal-title":"J Autoimmun"},{"key":"5307_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/ijms251910845","author":"J Martin","year":"2024","unstructured":"Martin J, Cheng Q, Laurent SA, Thaler FS, Beenken AE, Meinl E, Kr\u00f6nke G, Hiepe F, Alexander T (2024) B-cell maturation antigen (BCMA) as a biomarker and potential treatment target in systemic lupus erythematosus. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms251910845","journal-title":"Int J Mol Sci"},{"issue":"12","key":"5307_CR6","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1056\/NEJMoa2001180","volume":"383","author":"R Furie","year":"2020","unstructured":"Furie R, Rovin BH, Houssiau F, Malvar A, Teng YKO, Contreras G, Amoura Z, Yu X, Mok CC, Santiago MB et al (2020) Two-year, randomized, controlled trial of belimumab in lupus nephritis. N Engl J Med 383(12):1117\u20131128","journal-title":"N Engl J Med"},{"issue":"9767","key":"5307_CR7","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/S0140-6736(10)61354-2","volume":"377","author":"SV Navarra","year":"2011","unstructured":"Navarra SV, Guzm\u00e1n RM, Gallacher AE, Hall S, Levy RA, Jimenez RE, Li EK, Thomas M, Kim HY, Le\u00f3n MG et al (2011) Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 377(9767):721\u2013731","journal-title":"Lancet"},{"issue":"5","key":"5307_CR8","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1002\/art.40049","volume":"69","author":"W Stohl","year":"2017","unstructured":"Stohl W, Schwarting A, Okada M, Scheinberg M, Doria A, Hammer AE, Kleoudis C, Groark J, Bass D, Fox NL et al (2017) Efficacy and safety of subcutaneous belimumab in systemic lupus erythematosus: a fifty-two-week randomized, double-blind, placebo-controlled study. Arthritis Rheumatol 69(5):1016\u20131027","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"5307_CR9","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.kint.2021.08.027","volume":"101","author":"BH Rovin","year":"2022","unstructured":"Rovin BH, Furie R, Teng YKO, Contreras G, Malvar A, Yu X, Ji B, Green Y, Gonzalez-Rivera T, Bass D et al (2022) A secondary analysis of the Belimumab International Study in Lupus Nephritis trial examined effects of belimumab on kidney outcomes and preservation of kidney function in patients with lupus nephritis. Kidney Int 101(2):403\u2013413","journal-title":"Kidney Int"},{"issue":"4","key":"5307_CR10","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1136\/ard-2023-224854","volume":"83","author":"D Wu","year":"2024","unstructured":"Wu D, Li J, Xu D, Merrill JT, van Vollenhoven RF, Liu Y, Hu J, Li Y, Li F, Huang C et al (2024) Telitacicept in patients with active systemic lupus erythematosus: results of a phase 2b, randomised, double-blind, placebo-controlled trial. Ann Rheum Dis 83(4):475\u2013487","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"5307_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-019-0141-9","volume":"6","author":"HJ Anders","year":"2020","unstructured":"Anders HJ, Saxena R, Zhao MH, Parodis I, Salmon JE, Mohan C (2020) Lupus nephritis. Nat Rev Dis Primers 6(1):7","journal-title":"Nat Rev Dis Primers"},{"key":"5307_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2022.102871","volume":"132","author":"C Yu","year":"2022","unstructured":"Yu C, Li P, Dang X, Zhang X, Mao Y, Chen X (2022) Lupus nephritis: new progress in diagnosis and treatment. J Autoimmun 132:102871","journal-title":"J Autoimmun"},{"issue":"1","key":"5307_CR13","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s10067-024-07266-y","volume":"44","author":"HZ Jin","year":"2025","unstructured":"Jin HZ, Cai ML, Wang X, Li Z, Ma B, Niu L, Wang P, Pan HF, Li SD, Bao W et al (2025) Effectiveness and safety of Belimumab and Telitacicept in systemic lupus erythematosus: a real-world, retrospective, observational study. Clin Rheumatol 44(1):247\u2013256","journal-title":"Clin Rheumatol"},{"issue":"9","key":"5307_CR14","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1007\/s10157-024-02501-x","volume":"28","author":"X Huang","year":"2024","unstructured":"Huang X, Lin F, Chen H (2024) Efficacy and safety of telitacicept in patients with lupus nephritis: a single-center, real-world retrospective study. Clin Exp Nephrol 28(9):902\u2013909","journal-title":"Clin Exp Nephrol"},{"key":"5307_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ard.2025.09.007","author":"A Fanouriakis","year":"2025","unstructured":"Fanouriakis A, Kostopoulou M, Anders HJ, Andersen J, Aringer M, Beresford MW, Doria A, Frangou E, Furie R, Gladman DD et al (2025) EULAR recommendations for the management of systemic lupus erythematosus with kidney involvement: 2025 update. Ann Rheum Dis. https:\/\/doi.org\/10.1016\/j.ard.2025.09.007","journal-title":"Ann Rheum Dis"},{"key":"5307_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25168981","author":"A Roveta","year":"2024","unstructured":"Roveta A, Parodi EL, Brezzi B, Tunesi F, Zanetti V, Merlotti G, Francese A, Maconi AG, Quaglia M (2024) Lupus nephritis from pathogenesis to new therapies: an update. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms25168981","journal-title":"Int J Mol Sci"},{"issue":"7","key":"5307_CR17","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1002\/art.42462","volume":"75","author":"LS Evans","year":"2023","unstructured":"Evans LS, Lewis KE, DeMonte D, Bhandari JG, Garrett LB, Kuijper JL, Ardourel D, Wolfson MF, Debrot S, Mudri S et al (2023) Povetacicept, an enhanced dual APRIL\/BAFF antagonist that modulates B lymphocytes and pathogenic autoantibodies for the treatment of lupus and other B cell-related autoimmune diseases. Arthritis Rheumatol 75(7):1187\u20131202","journal-title":"Arthritis Rheumatol"},{"key":"5307_CR18","doi-asserted-by":"publisher","DOI":"10.3390\/biom13020367","author":"M Ayano","year":"2023","unstructured":"Ayano M, Horiuchi T (2023) Complement as a biomarker for systemic lupus erythematosus. Biomolecules. https:\/\/doi.org\/10.3390\/biom13020367","journal-title":"Biomolecules"},{"issue":"8","key":"5307_CR19","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1177\/09612033221097812","volume":"31","author":"L Sun","year":"2022","unstructured":"Sun L, Shen Q, Gong Y, Li Y, Lv Q, Liu H, Zhao F, Yu H, Qiu L, Li X et al (2022) Safety and efficacy of telitacicept in refractory childhood-onset systemic lupus erythematosus: a self-controlled before-after trial. Lupus 31(8):998\u20131006","journal-title":"Lupus"},{"issue":"1","key":"5307_CR20","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1177\/09612033221141253","volume":"32","author":"R Chen","year":"2023","unstructured":"Chen R, Fu R, Lin Z, Huang C, Huang W (2023) The efficacy and safety of telitacicept for the treatment of systemic lupus erythematosus: a real life observational study. Lupus 32(1):94\u2013100","journal-title":"Lupus"},{"issue":"3","key":"5307_CR21","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1136\/annrheumdis-2014-206897","volume":"75","author":"F Tamirou","year":"2016","unstructured":"Tamirou F, D\u2019Cruz D, Sangle S, Remy P, Vasconcelos C, Fiehn C, Ayala Guttierez MM, Gilboe IM, Tektonidou M, Blockmans D et al (2016) Long-term follow-up of the MAINTAIN nephritis trial, comparing azathioprine and mycophenolate mofetil as maintenance therapy of lupus nephritis. Ann Rheum Dis 75(3):526\u2013531","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"5307_CR22","doi-asserted-by":"publisher","first-page":"3934","DOI":"10.1002\/art.20666","volume":"50","author":"FA Houssiau","year":"2004","unstructured":"Houssiau FA, Vasconcelos C, D\u2019Cruz D, Sebastiani GD, de Ramon Garrido E, Danieli MG, Abramovicz D, Blockmans D, Mathieu A, Direskeneli H et al (2004) Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial. Arthritis Rheum 50(12):3934\u20133940","journal-title":"Arthritis Rheum"},{"issue":"5","key":"5307_CR23","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1093\/rheumatology\/keaa599","volume":"60","author":"M Okamoto","year":"2021","unstructured":"Okamoto M, Kitamura M, Sato S, Fujikawa K, Horai Y, Matsuoka N, Tsuboi M, Nonaka F, Shimizu T, Koga T et al (2021) Life prognosis and renal relapse after induction therapy in Japanese patients with proliferative and pure membranous lupus nephritis. Rheumatology (Oxford) 60(5):2333\u20132341","journal-title":"Rheumatology (Oxford)"},{"issue":"11","key":"5307_CR24","doi-asserted-by":"publisher","first-page":"3363","DOI":"10.1007\/s10067-022-06258-0","volume":"41","author":"K Du","year":"2022","unstructured":"Du K, Zhang X, Feng J, Zhong S, Qi J, Lin Z (2022) Renal response and its predictive factors of lupus nephritis: a 2-year real-world study of 56 hospital-based patients. Clin Rheumatol 41(11):3363\u20133371","journal-title":"Clin Rheumatol"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-026-05307-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11255-026-05307-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-026-05307-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T19:24:19Z","timestamp":1784921059000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11255-026-05307-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,24]]},"references-count":24,"alternative-id":["5307"],"URL":"https:\/\/doi.org\/10.1007\/s11255-026-05307-w","relation":{},"ISSN":["1573-2584"],"issn-type":[{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,24]]},"assertion":[{"value":"16 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"On behalf of all authors, the corresponding author states that there is no conflict of interest to disclose.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All participants signed informed consent and agreed to clinical data for clinical analysis at the time of admission. This study was conducted in accordance with the principles of the Declaration of Helsinki. The research ethics committee of Anhui Provincial Hospital approved the study protocol (NO.2025-RE-118).","order":2,"name":"Ethics","label":"Ethical approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"NA.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}}]}}